فهرست مطالب samyuktha lakkireddy

Zinc oxide (ZnO) nanoparticles have received growing attention for several biomedical applications. Nanoparticles proposed for these applications possess the potential to interact with biological components such as the blood, cells/ tissues following their administration into the body. Hence we carried out in vivo investigations in Swiss Albino Mice to understand the interaction of ZnO nanorods with the biological components following intravenous and oral routes of administration to assess nanoparticles safety. Intravenously injected ZnO nanorods were found to induce the significant reduction in the red blood cells and platelet counts. Elevated levels of serum enzymes such as serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase were observed following intravenous and oral administration. Also, increased levels (p

Cytochrome P450 is one of the major drug metabolizing enzyme families and its role in metabolism of cancer drugs cannot be less emphasized. The association between single nucleotide polymorphisms (SNPs) in CYP1A1 and pathogenesis of chronic myeloid leukemia (CML) has been investigated in several studies, but the results observed vary based on varied risk factors. The objective of this study was to investigate the risk factors associated with the CYP1A1*2C [rs1048943: A>G] polymorphism in CML patients and its role in therapeutic response to imatinib mesylate (IM) affecting clinico-pathological parameters, in the Indian population. In this case-control study, CYP1A1*2C was analysed in CML patients. After obtaining approval from the Ethics Committee of oncology hospital, we collected blood samples from 132 CML patients and 140 matched controls. Genomic DNA was extracted and all the samples were analysed for the presence of the CYP1A1*2C polymorphism using allele-specific polymerase chain reaction, and we examined the relationship of genotypes with risk factors such as gender, age, phase of the disease and other clinical parameters. We observed a significant difference in the frequency distribution of CYP1A1*2C genotypes AA (38 vs. 16%, P=0.0001), AG (57 vs. 78%, P=0.0002) and GG (5 vs. 6%, P=0.6635) between patients and controls. In terms of response to IM therapy, significant variation was observed in the frequencies of AA vs. AG in major (33 vs. 67%) and poor 62 vs. 31%) hematological responders, and AA vs. AG in major (34 vs. 65%) and poor (78 vs. 22%) cytogenetic responders. However, the patients with the GG homozygous genotype did not show any significant therapeutic outcome. The higher frequency of AG in controls indicates that AG may play a protective role against developing CML. We also found that patients with the AG genotype showed favorable treatment response towards imatinib therapy, indicating that this polymorphism could serve as a good therapeutic marker in predicting response to such therapy.